Minghui Pharma sells Japanese rights to its Phase 3 thyroid eye disease drug for $110 million upfront

Minghui Pharmaceutical, a Shanghai‑based biotech, has agreed to transfer the Japanese commercial rights for its late‑stage thyroid eye disease candidate to a specialty pharmaceutical company.

The drug is currently in Phase 3 trials, targeting an autoimmune condition that can cause vision loss and eye discomfort.

The buyer, a 106‑year‑old specialty firm with a long history in thyroid hormone products, will pay $110 million upfront for the rights.

The transaction gives Minghui a substantial cash infusion while providing the buyer a ready‑to‑market asset in a niche ophthalmic market.